Active substance
Results for the substance somatrogon
2 results
About this active substance
Somatrogon is a recombinant human growth hormone analog used in the treatment of growth hormone deficiency (GHD) in children and adults. It is designed to have a prolonged duration of action, allowing for weekly administration, unlike traditional growth hormone therapies that require daily injections.
Somatrogon works by stimulating bone and muscle growth, promoting protein and lipid metabolism, and supporting normal development in patients with growth hormone deficiency. It is administered as a subcutaneous injection, with the dose adjusted based on body weight and individual patient response.
Common side effects include injection site reactions, headache, nausea, and muscle pain. In rare cases, severe adverse reactions such as hyperglycemia or intracranial hypertension may occur. Regular monitoring of growth, hormone levels, and overall health is essential during treatment.
Somatrogon represents an innovative therapeutic option for patients with growth hormone deficiency, offering more convenient administration and comparable clinical outcomes to traditional therapies.
Somatrogon works by stimulating bone and muscle growth, promoting protein and lipid metabolism, and supporting normal development in patients with growth hormone deficiency. It is administered as a subcutaneous injection, with the dose adjusted based on body weight and individual patient response.
Common side effects include injection site reactions, headache, nausea, and muscle pain. In rare cases, severe adverse reactions such as hyperglycemia or intracranial hypertension may occur. Regular monitoring of growth, hormone levels, and overall health is essential during treatment.
Somatrogon represents an innovative therapeutic option for patients with growth hormone deficiency, offering more convenient administration and comparable clinical outcomes to traditional therapies.